Discovery of a Novel Inhibitor of Coronavirus 3CL Protease for the Potential Treatment of COVID-19

A pneumonia outbreak associated with a new coronavirus of probable bat origin

Zhou, P., Yang, X.-L., Wang, X.-G., Hu, B., Zhang, L., Zhang, W., Si, H.-R., Zhu, Y., Li, B., Huang, C.-L., et al. (2020) · Nature · doi:10.1038/s41586-020-2012-7 · Cited by 21,969 · see citing works

Tissue-based map of the human proteome

Uhlén, M., Fagerberg, L., Hallström, B. M., Lindskog, C., Oksvold, P., Mardinoglu, A., Sivertsson, Å., Kampf, C., Sjöstedt, E., Asplund, A., et al. (2015) · Science · doi:10.1126/science.1260419 · Cited by 15,286 · see citing works

Revised methods for the Salmonella mutagenicity test

Maron, D. M., & Ames, B. N. (1983) · Mutation Research/Environmental Mutagenesis and Related Subjects · doi:10.1016/0165-1161(83)90010-9 · Cited by 7,398 · see citing works

Remdesivir for the Treatment of Covid-19 — Final Report

Beigel, J. H., Tomashek, K. M., Dodd, L. E., Mehta, A. K., Zingman, B. S., Kalil, A. C., Hohmann, E., Chu, H. Y., Luetkemeyer, A., Kline, S., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2007764 · Cited by 7,267 · see citing works

Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors

Zhang, L., Lin, D., Sun, X., Curth, U., Drosten, C., Sauerhering, L., Becker, S., Rox, K., & Hilgenfeld, R. (2020) · Science · doi:10.1126/science.abb3405 · Cited by 3,275 · see citing works

Characterization of a Novel Coronavirus Associated with Severe Acute Respiratory Syndrome

Rota, P. A., Oberste, M. S., Monroe, S. S., Nix, W. A., Campagnoli, R. P., Icenogle, J. P., Peñaranda, S., Bankamp, B., Maher, K., Chen, M., et al. (2003) · Science · doi:10.1126/science.1085952 · Cited by 2,477 · see citing works

The Genome Sequence of the SARS-Associated Coronavirus

Marra, M. A., Jones, S. J. M., Astell, C. R., Holt, R. A., Brooks-Wilson, A. R., Butterfield, Y. S. N., Khattra, J. S., Asano, J. K., Barber, S., Chan, S. Y., et al. (2003) · Science · doi:10.1126/science.1085953 · Cited by 2,017 · see citing works

Data, disease and diplomacy: GISAID's innovative contribution to global health

Elbe, S., & Buckland‐Merrett, G. (2017) · Global Challenges · doi:10.1002/gch2.1018 · Cited by 1,928 · see citing works

Coronavirus Main Proteinase (3CL pro ) Structure: Basis for Design of Anti-SARS Drugs

Anand, K., Ziebuhr, J., Wadhwani, P., Mesters, J. R., & Hilgenfeld, R. (2003) · Science · doi:10.1126/science.1085658 · Cited by 1,734 · see citing works

Boceprevir for Previously Treated Chronic HCV Genotype 1 Infection

Bacon, B. R., Gordon, S. C., Lawitz, E., Marcellin, P., Vierling, J. M., Zeuzem, S., Poordad, F. F., Goodman, Z. D., Sings, H. L., Boparai, N., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009482 · Cited by 1,620 · see citing works

Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development

REDFERN, W., Carlsson, L. G., DAVIS, A., LYNCH, W., MACKENZIE, I., PALETHORPE, S., Siegl, P. K. S., Strang, I., Sullivan, A. K., & WALLIS, R. (2003) · Cardiovascular Research · doi:10.1016/s0008-6363(02)00846-5 · Cited by 1,535 · see citing works

Prediction of Human Clearance of Twenty-Nine Drugs from Hepatic Microsomal Intrinsic Clearance Data: An Examination of In Vitro Half-Life Approach and Nonspecific Binding to Microsomes

Obach, R. S. (1999) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)14938-0 · Cited by 1,232 · see citing works

An Overview of Severe Acute Respiratory Syndrome–Coronavirus (SARS-CoV) 3CL Protease Inhibitors: Peptidomimetics and Small Molecule Chemotherapy

Pillaiyar, T., Manickam, M., Namasivayam, V., Hayashi, Y., & Jung, S. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01461 · Cited by 773 · see citing works

SynergyFinder: a web application for analyzing drug combination dose–response matrix data

Ianevski, A., He, L., Aittokallio, T. A., & Tang, J. P. (2017) · Bioinformatics · doi:10.1093/bioinformatics/btx162 · Cited by 535 · see citing works

The Simcyp ^® Population-based ADME Simulator

Jamei, M., Marciniak, S., Feng, K., Barnett, A., Tucker, G., & Rostami-Hodjegan, A. (2009) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425250802691074 · Cited by 533 · see citing works

2019 Novel Coronavirus (COVID-19) Outbreak: A Review of the Current Literature

Şahin, A. R., Erdogan, A., Ağaoğlu, P. M., Dineri, Y., Cakirci, A. Y., Senel, M. E., Okyay, R. A., & Tasdogan, A. M. (2020) · Eurasian Journal of Medicine and Oncology · doi:10.14744/ejmo.2020.12220 · Cited by 525 · see citing works

Discovery of Ketone-Based Covalent Inhibitors of Coronavirus 3CL Proteases for the Potential Therapeutic Treatment of COVID-19

Hoffman, R. L., Kania, R. S., Brothers, M. A., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01063 · Cited by 508 · see citing works

HIV protease inhibitors: a review of molecular selectivity and toxicity

Wang, Y., Lv, Z., & Chu, Y. (2015) · HIV/AIDS - Research and Palliative Care · doi:10.2147/hiv.s79956 · Cited by 455 · see citing works

A Mouse-Adapted SARS-Coronavirus Causes Disease and Mortality in BALB/c Mice

Roberts, A., Deming, D., Paddock, C. D., Cheng, A., Yount, B. L., Vogel, L., Herman, B. D., Sheahan, T., Heise, M. T., Genrich, G. L., et al. (2007) · PLoS Pathogens · doi:10.1371/journal.ppat.0030005 · Cited by 447 · see citing works

Mutagen testing using TRP+ reversion in Escherichia coli

Green, M. H. L., & Muriel, W. J. (1976) · Mutation Research/Environmental Mutagenesis and Related Subjects · doi:10.1016/0165-1161(76)90076-5 · Cited by 441 · see citing works

Dose-response curve slope sets class-specific limits on inhibitory potential of anti-HIV drugs

Shen, L., Peterson, S., Sedaghat, A. R., McMahon, M. A., Callender, M., Zhang, H., Zhou, Y., Pitt, E., Anderson, K. S., Acosta, E. P., et al. (2008) · Nature Medicine · doi:10.1038/nm1777 · Cited by 331 · see citing works

Development of a new permeability assay using low‐efflux MDCKII cells

Di, L., Whitney‐Pickett, C., Umland, J. P., Zhang, H., Zhang, X., Gebhard, D. F., Lai, Y., Federico, J. J., Davidson, R. E., Smith, R., et al. (2011) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.22674 · Cited by 328 · see citing works

Conservation of substrate specificities among coronavirus main proteases

Hegyi, A., & Ziebuhr, J. (2002) · Journal of General Virology · doi:10.1099/0022-1317-83-3-595 · Cited by 324 · see citing works

Charting the human proteome: Understanding disease using a tissue-based atlas

Uhlén, M., Pontén, F., & Lindskog, C. (2015) · Science · doi:10.1126/science.347.6227.1274-c · Cited by 262 · see citing works

Use of Plasma and Brain Unbound Fractions to Assess the Extent of Brain Distribution of 34 Drugs: Comparison of Unbound Concentration Ratios to in Vivo P-Glycoprotein Efflux Ratios

Kalvass, J. C., Maurer, T. S., & Pollack, G. M. (2007) · Drug Metabolism and Disposition · doi:10.1124/dmd.106.012294 · Cited by 227 · see citing works

Evaluating the 3C-like protease activity of SARS-Coronavirus: Recommendations for standardized assays for drug discovery

Grum-Tokars, V. L., Ratia, K. M., Begaye, A., Baker, S. C., & Mesecar, A. D. (2007) · Virus Research · doi:10.1016/j.virusres.2007.02.015 · Cited by 187 · see citing works

Ligand-induced Dimerization of Middle East Respiratory Syndrome (MERS) Coronavirus nsp5 Protease (3CLpro)

Tomar, S., Johnston, M. L., John, S. E. S., Osswald, H. L., Nyalapatla, P. R., Paul, L. N., Ghosh, A. K., Denison, M. R., & Mesecar, A. D. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.651463 · Cited by 169 · see citing works

pH-Dependent Solubility and Permeability Criteria for Provisional Biopharmaceutics Classification (BCS and BDDCS) in Early Drug Discovery

Varma, M. V. S., Gardner, I. B., Steyn, S. J., Nkansah, P., Rotter, C. J., Whitney‐Pickett, C., Zhang, H., Di, L., Cram, M., Fenner, K. S., et al. (2012) · Molecular Pharmaceutics · doi:10.1021/mp2004912 · Cited by 162 · see citing works

Design and Synthesis of Peptidomimetic Severe Acute Respiratory Syndrome Chymotrypsin-like Protease Inhibitors

Ghosh, A. K., Xi, K., Ratia, K. M., Santarsiero, B. D., Fu, W., Harcourt, B. H., Rota, P. A., Baker, S. C., Johnson, M. E., & Mesecar, A. D. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm050548m · Cited by 142 · see citing works

Molecular Determinants of Severe Acute Respiratory Syndrome Coronavirus Pathogenesis and Virulence in Young and Aged Mouse Models of Human Disease

Frieman, M. B., Yount, B. L., Agnihothram, S., Page, C., Donaldson, E., Roberts, A., Vogel, L., Woodruff, B., Scorpio, D. G., Subbarao, K., et al. (2011) · Journal of Virology · doi:10.1128/jvi.05957-11 · Cited by 141 · see citing works

Drug repurposing screens identify chemical entities for the development of COVID-19 interventions

Bakowski, M. A., Beutler, N., Wolff, K. C., Kirkpatrick, M. G., Chen, E., Nguyen, T.-T., Riva, L., Shaabani, N., Parren, M., Ricketts, J., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-23328-0 · Cited by 140 · see citing works

Role of Multiple Drug Resistance Protein 1 in Neutral but Not Acidic Glycosphingolipid Biosynthesis

Rosa, M. F. D., Sillence, D. J., Ackerley, C. A., & Lingwood, C. A. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m305645200 · Cited by 116 · see citing works

Coronavirus Protein Processing and RNA Synthesis Is Inhibited by the Cysteine Proteinase Inhibitor E64d

Kim, J. C., Spence, R. A., Currier, P. F., et al. (1995) · Virology · doi:10.1006/viro.1995.1123 · Cited by 101 · see citing works

Coronaviruses Resistant to a 3C-Like Protease Inhibitor Are Attenuated for Replication and Pathogenesis, Revealing a Low Genetic Barrier but High Fitness Cost of Resistance

Deng, X., John, S. E. S., Osswald, H. L., et al. (2014) · Journal of Virology · doi:10.1128/jvi.01528-14 · Cited by 96 · see citing works

Clinical pharmacology of HIV protease inhibitors: focus on saquinavir, indinavir, and ritonavir.

Hoetelmans, R. M. W., Koks, C. H. W., Beijnen, J. H., et al. (1997) · Pharmacy World & Science · doi:10.1023/a:1008629608556 · Cited by 93 · see citing works

Targeting zoonotic viruses: Structure-based inhibition of the 3C-like protease from bat coronavirus HKU4—The likely reservoir host to the human coronavirus that causes Middle East Respiratory Syndrome (MERS)

John, S. E. S., Tomar, S., Stauffer, S. R., & Mesecar, A. D. (2015) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2015.06.039 · Cited by 92 · see citing works

1H/31P NMR pH indicator series to eliminate the glass electrode in NMR spectroscopic pKa determinations

Szakács, Z., Hägele, G., & Roman, T. Y. K. A. (2004) · Analytica Chimica Acta · doi:10.1016/j.aca.2004.07.005 · Cited by 79 · see citing works

Effect of Antiretroviral Therapy on Viral Load, CD4 Cell Count, and Progression to Acquired Immunodeficiency Syndrome in a Community Human Immunodeficiency Virus–Infected Cohort

Erb, P. (2000) · Archives of Internal Medicine · doi:10.1001/archinte.160.8.1134 · Cited by 70 · see citing works

Arrhythmogenic mechanisms of non‐sedating antihistamines

Yap, Y. G., & Camm, A. J. (1999) · Clinical & Experimental Allergy · doi:10.1046/j.1365-2222.1999.0290s3174.x · Cited by 70 · see citing works

A Critical Subset Model Provides a Conceptual Basis for the High Antiviral Activity of Major HIV Drugs

Shen, L., Rabi, S. A., Sedaghat, A. R., Shan, L., Lai, J., Xing, S., & Siliciano, R. F. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002304 · Cited by 68 · see citing works

An improved method for the determination of distribution coefficients

Stopher, D. A., & McClean, S. (1990) · Journal of Pharmacy and Pharmacology · doi:10.1111/j.2042-7158.1990.tb05373.x · Cited by 63 · see citing works

Biosynthesis of Drug Metabolites and Quantitation Using NMR Spectroscopy for Use in Pharmacologic and Drug Metabolism Studies

Walker, G. S., Bauman, J. N., Ryder, T. F., et al. (2014) · Drug Metabolism and Disposition · doi:10.1124/dmd.114.059204 · Cited by 63 · see citing works

A case for prodrugs: Fosphenytoin

Stella, V. J. (1996) · Advanced Drug Delivery Reviews · doi:10.1016/0169-409x(95)00112-k · Cited by 62 · see citing works

Amprenavir Inhibitory Quotient and Virological Response in Human Immunodeficiency Virus-Infected Patients on an Amprenavir-Containing Salvage Regimen without or with Ritonavir

Duval, X., Lamotte, C., Race, E., et al. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.2.570-574.2002 · Cited by 56 · see citing works

A Mouse Model for Betacoronavirus Subgroup 2c Using a Bat Coronavirus Strain HKU5 Variant

Agnihothram, S., Yount, B. L., Donaldson, E., Huynh, J., Menachery, V. D., Gralinski, L. E., Graham, R. L., Becker, M. M., Tomar, S., Scobey, T., et al. (2014) · mBio · doi:10.1128/mbio.00047-14 · Cited by 56 · see citing works

Quantifying antiviral activity optimizes drug combinations against hepatitis C virus infection

Koizumi, Y., Ohashi, H., Nakajima, S., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1610197114 · Cited by 54 · see citing works

Rate-dependence of antiarrhythmic and proarrhythmic properties of class I and class III antiarrhythmic drugs

Weirich, J., & Antoni, H. (1998) · Basic Research in Cardiology · doi:10.1007/s003950050236 · Cited by 53 · see citing works

Temperature-Sensitive Mutants and Revertants in the Coronavirus Nonstructural Protein 5 Protease (3CLpro) Define Residues Involved in Long-Distance Communication and Regulation of Protease Activity

Stobart, C. C., Lee, A. S., Lu, X., et al. (2012) · Journal of Virology · doi:10.1128/jvi.06754-11 · Cited by 43 · see citing works

Broad-spectrum inhibition of coronavirus main and papain-like proteases by HCV drugsPreprint

Anson, B. J., Chapman, M. E., Lendy, E. K., et al. (2020) · doi:10.21203/rs.3.rs-26344/v1 · Cited by 42 · see citing works

Pharmacokinetic/Pharmacodynamic Predictors of Clinical Potency for Hepatitis C Virus Nonnucleoside Polymerase and Protease Inhibitors

Reddy, M. B., Morcos, P. N., Pogam, S. L., et al. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.06283-11 · Cited by 41 · see citing works

Recent Advances in Hepatitis C Virus Treatment: Review of HCV Protease Inhibitor Clinical Trials

Chary, A., & Holodniy, M. (2010) · Reviews on Recent Clinical Trials · doi:10.2174/157488710792007293 · Cited by 38 · see citing works

Pharmacokinetics of fosfluconazole and fluconazole following multiple intravenous administration of fosfluconazole in healthy male volunteers

Sobue, S., Tan, K., Layton, G. R., Eve, M. D., & Sanderson, J. B. (2004) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2004.02107.x · Cited by 35 · see citing works

N-(3,4-dimethoxyphenethyl)-4-(6,7-dimethoxy-3,4-dihydroisoquinolin-2[1H]-yl)-6,7-dimethoxyquinazolin-2-amine (CP-100,356) as a “chemical knock-out equivalent” to assess the impact of efflux transporters on oral drug absorption in the rat

Kalgutkar, A. S. S., Frederick, K. S., Chupka, J., et al. (2009) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21756 · Cited by 32 · see citing works

Statistical Methods for Analysis of Time-Dependent Inhibition of Cytochrome P450 Enzymes

Yates, P. D., Eng, H. F., Di, L., et al. (2012) · Drug Metabolism and Disposition · doi:10.1124/dmd.112.047233 · Cited by 31 · see citing works

X-ray structure and inhibition of the feline infectious peritonitis virus 3C-like protease: Structural implications for drug design

John, S. E. S., Therkelsen, M. D., Nyalapatla, P. R., et al. (2015) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2015.10.023 · Cited by 25 · see citing works

Estimation of inhibitory quotient using a comparative equilibrium dialysis assay for prediction of viral response to hepatitis C virus inhibitors

Mo, H., Yang, C., Wang, K., et al. (2010) · Journal of Viral Hepatitis · doi:10.1111/j.1365-2893.2010.01314.x · Cited by 22 · see citing works

X-Ray Structure and Inhibition of 3C-like Protease from Porcine Epidemic Diarrhea Virus

John, S. E. S., Anson, B. J., & Mesecar, A. D. (2016) · Scientific Reports · doi:10.1038/srep25961 · Cited by 22 · see citing works

Development of an Efficient Enzyme Production and Structure-Based Discovery Platform for BACE1 Inhibitors

Yen, Y., Kammeyer, A. M., Jensen, K. C., Tirlangi, J., Ghosh, A. K., & Mesecar, A. D. (2019) · Biochemistry · doi:10.1021/acs.biochem.9b00714 · Cited by 15 · see citing works

A comparative analysis of SARS-CoV-2 antivirals in human airway models characterizes 3CL(pro) inhibitor PF-00835231 as a potential new treatment for COVID-19Preprint

de Vries, M., Mohamed, A., Prescott, R. A., Valero-Jimenez, A. M., Desvignes, L., O’Connor, R., Steppan, C. M., Devlin, J. C., Ivanova, E. N., Herrera, A. M., et al. (2021) · PubMed Central · doi:10.1101/2020.08.28.272880 · Cited by 15 · see citing works

Pharmacokinetics of Fluconazole and Fosfluconazole after Intraperitoneal Administration to Peritoneal Dialysis Rats

Aoyama, T., Ogata, K., Shimizu, M., et al. (2005) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.20.485 · Cited by 11 · see citing works

Suggested format for articles to be submitted to “Genetic Toxicology Testing”

Wassom, J. S., & Malling, H. V. (1976) · Mutation Research/Genetic Toxicology · doi:10.1016/0165-1218(76)90015-x · Cited by 4 · see citing works

Understanding the determinants for substrate recognition, regulation of enzymatic activity and the development of broad-spectrum inhibitors of coronavirus 3-chymotrypsin-like proteases

Tomar, S. (2015) · Purdue e-Pubs (Purdue University System) · Cited by 3 · see citing works

In VivoMetabolite Kinetics

Yang, Z. (2008) · doi:10.1002/9780470439265.ch4 · Cited by 3 · see citing works

PROTAC targeted protein degraders: the past is prologue

Békés, M., Langley, D. R., & Crews, C. M. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00371-6 · Cited by 3,395 · see citing works

An oral SARS-CoV-2 M ^pro inhibitor clinical candidate for the treatment of COVID-19

Owen, D. R., Allerton, C. M. N., Anderson, A. S., Aschenbrenner, L., Avery, M., Berritt, S., Boras, B., Cardin, R. D., Carlo, A., Coffman, K. J., et al. (2021) · Science · doi:10.1126/science.abl4784 · Cited by 2,033 · see citing works

SARS-CoV-2 M ^pro inhibitors with antiviral activity in a transgenic mouse model

Qiao, J., Li, Y.-S., Zeng, R., Liu, F.-L., Luo, R.-H., Huang, C., Wang, Y.-F., Zhang, J., Quan, B., Shen, C., et al. (2021) · Science · doi:10.1126/science.abf1611 · Cited by 465 · see citing works

A critical overview of computational approaches employed for COVID-19 drug discovery

Muratov, E. N., Amaro, R., Andrade, C. H., Brown, N., Ekins, S., Fourches, D., Isayev, O., Kozakov, D., Medina-Franco, J. L., Merz, K. M., et al. (2021) · Chemical Society Reviews · doi:10.1039/d0cs01065k · Cited by 206 · see citing works

Progress in HIV-1 Protease Inhibitor Prodrugs

Xu-chang, H. (2005) · Yaoxue jinzhan

Protease and Protease Inhibitor Activity in Rat Skeletal Muscle during Growth, Protein Deficiency and Fasting

Noguchi, T., Miyazawa, E., & Kametaka, M. (1974) · Agricultural and Biological Chemistry · doi:10.1080/00021369.1974.10861158 · Cited by 5 · see citing works

Protease and Protease Inhibitor Activity in Rat Skeletal Muscle during Growth, Protein Deficiency and Fasting

(1974) · doi:10.1271/bbb1961.38.253 · Cited by 18 · see citing works

Preliminary Characterization of Protease Inhibitor from Bacteria-Associated with Sponge from Panggang Island, Seribu Islands

Nurhayati, ‪., Suhartono, M. T., Nuraida, L., et al. (2006) · DOAJ (DOAJ: Directory of Open Access Journals) · doi:10.4308/hjb.13.2.58

A 6-Base Pair Insertion in the Protease Gene of HIV Type 1 Detected in a Protease Inhibitor-Naive Patient Is Not Associated with Indinavir Treatment Failure

Stürmer, M., Staszewski, S., Doerr, H. W., et al. (2003) · AIDS Research and Human Retroviruses · doi:10.1089/088922203322588314 · Cited by 15 · see citing works